{"groups":[{"description":"Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.\n\nromidepsin: Given IV\n\nlenalidomide: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"FG000","title":"Treatment (Romidepsin, Lenalidomide)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"No Response"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Screen failure"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Disease Progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"}],"type":"Cycle 1"},{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"Cycle 2"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"Cycle 3"},{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"1st Response Assessment"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Study Treatment Period: Cycles 1-3"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"Cycle 4"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"Cycle 5"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"Cycle 6"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"2nd Response Assessment"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Study Treatment Period: Cycles 4-6"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"Cycle 7"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"Cycle 8"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"Cycle 9"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"3rd Response Assessment"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Study Treatment Period: Cycles 7-9"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Disease Progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"Cycle 10"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"Cycle 11"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"Cycle 12"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Study Treatment Period: Cycles 10-12"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"15"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Still in follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"29"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Survival Follow-up"}],"recruitmentDetails":"The target population for this phase II study is patients with histologically confirmed (previously untreated) peripheral T-cell lymphoma (PTCL). Northwestern University will serve was the lead site and coordinating center for this study. Participating sites included Weill Cornell Medical College, and City of Hope. Enrollment began on 06/11/2015 at Northwestern University, 05/24/2017 at City of Hope, 12/14/2016 at Cornell University."}